First Biosimilar Reviews Raise Questions About Differences In Asia
This article was originally published in PharmAsia News
Executive Summary
Regulators are beginning to decide on the acceptability of imitation biotech products, despite a continuing inability to fully ascertain how they differ from the brand products, or what the perceived differences actually mean
You may also be interested in...
PhRMA Urges Japan To Create Separate Regulations For Biosimilars
TOKYO - The Pharmaceutical Research and Manufacturers of America called on Japan to create a separate regulatory structure for biosimilar drugs from branded biologics, a day after the Ministry of Health, Labor and Welfare released a draft biosimilar guideline Sept. 17
PhRMA Urges Japan To Create Separate Regulations For Biosimilars
TOKYO - The Pharmaceutical Research and Manufacturers of America called on Japan to create a separate regulatory structure for biosimilar drugs from branded biologics, a day after the Ministry of Health, Labor and Welfare released a draft biosimilar guideline Sept. 17
Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment
TOKYO - Japan's Ministry of Health, Labor and Welfare Sept. 17 posted draft guidance on follow-on biologics, or biosimilars, a move that could make Japan among the first group of large economies to set a safety and regulatory framework for the new copycat breed of biologic therapies